IHS Chemical Week

People & Business :: Companies

BMS Extends Lonza Contract

8:17 AM MDT | July 26, 2007 | Alex Scott

Bristol-Myers Squibb (BMS) says it has agreed to extend a supply agreement with Lonza, in which Lonza will manufacture BMS’s biologic rheumatoid arthritis drug Orencia until 2014. Orencia was approved by FDA in 2005 and launched in the U.S. in February 2006. The product generated sales of $32 million in the final quarter of 2006. Lonza will produce the product at its Portsmouth, NH facility. Separately, Lonza says it has granted UCB a non-exclusive license to its glutamine synthetase (GS) gene expression system for manufacturing therapeutic recombinant...

This information is only available to Chemical Week subscribers.

Username:
Password:

Forgot your user ID or password?
Click here to have it sent to you.



Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.

 














 
contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa